参考文献/References:
［1］ SMITH JA，ALBEITZ J，BEGLEY C，CAFFERY B，NICHOLS K，SCHAUMBERG D，et al.The epidemiology of dry eye disease：report of the epidemiology subcommittee of the international Dry Eye WorkShop［J］.Ocul Surf，2007，5（2）：93-107.
［2］ LEMP M，BAUDOUIN C，BAUM J，DOGRU M，FOULKS G，KINOSHITA S，et al.The definition and classification of dry eye disease：report of the Definition and Classification Subcommittee of the Internetional Dry Eye WorkShop［J］.Ocul Surf，2007，5（2）：75-92.
［3］ RHEN T，CIDLOWSKI JA.Antiinflammatory action of glucocorticoids-new mechanisms for old drugs［J］.N Engl J Med，2005，353（16）：1711-1723.
［4］ PFLUGFELDER SC，MASKIN SL，ANDERSON B，CHODOSH J，HOLLAND EJ，DE PAIVA CS，et al.A randomized，double-masked，placebo-controlled，multicenter comparison of loteprednol etabonate ophthalmic suspension，0.5%，and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance［J］.Am J Ophthalmol，2004，138（3）：444-457.
［5］ AVUNDUK AM，AVUNDUK MC，VARNELL ED，KAUFMAN HE.The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients：a clinical and immunocytochemical study［J］.Am J Ophthalmol，2003，136（4）：593.
［6］ LIN T，GONG L.Topical fluorometholone treatment for ocular dryness in patients with Sjgren syndrome：a randomized clinical trial in China［J］.Medicine（Baltimore），2015，94（7）：551.
［7］ VILLANI E，GAROLI E，TERMINE V，PICHI F，RATIQLIA R，NUCCI P.Corneal confocal microscopy in dry eye treatment with corticosteroids［J］.Optom Vis Sci，2015，92（9）：290-295.
［8］ HESSEN M，AKPEK EK.Dry eye：an inflammatory ocular disease［J］.J Ophthalmic Vis Res，2014，9（2）：240-250.
［9］ STERN ME，GAO J，SIEMASKO KF，BEUERMAN RW，PFLUGFELDER SC.The role of the lacrimal gland functional unit in the pathophysiology of dry eye［J］.Exp Eye Res，2004，78（3）：409-461.
［10］ ZHOU XQ，WEI RL.Topical cyclosporine A in the treatment of dry eye：a systematic review and meta-analysis［J］.Cornea，2014，33（7）：760-767.
［11］ STONECIPHER KG，TORKILDSEN GL，OUSLER GW，MORRIS S，VILLANUEVA L，HOLLANDER DA.The impact study：a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye［J］.Clin Ophthalmol，2016，10（5）：887-895.
［12］ DASTJERDI MH，HAMRAH P，DANA R.High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen［J］.Cornea，2009，28（10）：1091-1096.
［13］ MESSMER EM.The pathophysiology，diagnosis，and treatment of dry eye disease［J］.Dtsch Arztebl In，2015，112（5）：71-81.
［14］ PREZ-RICO C，GERMAIN F，CASTRO-REBOLLO M，MORE-NO-SALQUEIRO A，TEUS M.Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease［J］.Int J Ophthalmol，2013，6（4）：471-474.
［15］ LEONARDI A，VAN SETTEN G，AMRANE M，ISMAIL D，GARRIQUE JS，FIQUEIREDO FC，et al.Efficacy and safety of 0.1%cyclosporine A cationic emulsion in the treatment of severe dry eye disease：a multicenter randomized trial［J］.Eur J Ophthalmol，2016，26（4）：287-296.
［16］ THOMSON AW，BONHAM CA，ZEEVI A.Mode of action of tacrolimus （FK506）：molecular and cellular mechanisms［J］.Ther Drug Monit，1995，17（6）：584-591.
［17］ ZHENG X，ZHANG X，LIU X，MU W，YANG W，LIU Y，et al.Patient with neuromyelitis optica spectrum disorder combine with Sjgren’s syndrome relapse free following tacrolimus treatment［J］.Intern Med，2014，53（20）：2377-2380.
［18］ RYU EH，KIM JM，LADDHA PM，CHUNG ES，CHUNG TY.Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis［J］.Korean J Ophthalmol，2012，26（4）：241-247.
［19］ MOSCOVICI BK，HOLZCHUH R，SAKASSEGAWA-NAVES FE，HOSHINORUIZ DR，VILLAALBERS MB，SANTO RM，et al.Treatment of Sjgren’s syndrome dry eye using 0.03% tacrolimus eye drop：prospective double-blind randomized study［J］.Cont Lens Anterior Eye，2015，38（5）：373-378.
［20］ BIAN F，PELEGRINO FS，HENRIKSSON JT，PFLUGFELDER SC，VOLPE EA，LI DQ，et al.Differential effects of dexamethasone and doxycyline on inflammation and MMP production in murine alkali-burned corneas associated with dry eye［J］.Ocul Surf，2016，14（2）：242-254.
［21］ DE PAIVA CS，CORRALES RM，VILLARREAL AL，FARLEY W，LI DQ，STERN ME，et al.Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycine［J］.Invest Ophthalmol Vis Sci，2006，47（7）：2847-2856.
［22］ ARMAN A，DEMIRSEREN DD，TAKMAZ T.Treatment of ocular rosacea：compactive study of topical cyclosporine and oral doxycycline［J］.Int J Ophthalmol，2015，8（3）：544-549.
［23］ SHIM J，PARK C，LEE HS，PARK MS，LIM HT，CHAUHAN S，et al.Change in prostaglandin expression levels and synthesizing activities in dry eye disease［J］.Ophthalmology，2012，119（11）：2211-2219.
［24］ MURAT D，KAZUO T.Pharmacotherapy of dry eye［J］.Expert Opin Pharmacother，2011，12（3）：325-334.
［25］ ARAGONA P，STILO A，FERRERI F，MOBRICI M.Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjgren’s syndrome patients［J］.Eye（Lond），2005，19（5）：535-539.
［26］ JI H，PETTIT A，OHMURA K，ORTIZ-LOPEZ A，DUCHATELLE V，DEGOTT C，et al.Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis［J］.J Exp Med，2002，196（1）：77-85.
［27］ MONDY P，BRAMA T，FISHER J，GEMELLI CN，CHEE K，KEEGAN A，et al.Sustained benefits of autologous serum eye drops on self-reported ocular symptomes and vision-related quality of life in Australian patients with dry eye and corneal epithelial defects［J］.Transfus Apher Sci，2015，53（3）：404-411.
［28］ VERSURA P，PROFAZIO V，BUZZI M，STANCARI A，ARPINATI M，MALAVOLTA N，et al.Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye［J］.Cornea，2013，32（4）：412-418.
［29］ YOON KC，JEONG IY，IM SK，PARK YG，KIM HJ，CHOI J.Therapeutic effect of umbilical cord serum for the treatment of dry eye associated with graft-versus-host disease［J］.Bone Marrow Transplant，2007，39（4）：231-235.
［30］ NA KS，KIM MS.Allogenic serum eye drop for the treatment of dry eye patients with chronic graft-versus-host disease［J］.J Ocul Pharmacol Ther，2012，28（5）：479-483.
［31］ GABAY C，PORTER B，FANTUZZI G，AREND WP.Mouse IL-1 receptor antagonist isoforms：complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo［J］.J Immunol，1997，159（12）：5905-5913.
［32］ OKANOBO A，CHAUHAN SK，DASTJERDI MH，KODATI S，DANA R.Efficacy of topical blockade of interleukin-1 in experimental dry eye disease［J］.Am J Ophthalmol，2012，154（1）：63-71.
［33］ SERHAN CN，CHIANG N，VAN DYKE TE.Resolving inflammation：dual anti-inflammatory and pro-resolution lipid mediators［J］.Nat Rev Immunol，2008，8（5）：349-361.
［34］ LI N，HE J，SCHWARTZ CE，GJORSTRUP P，BAZAN HE.Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model［J］.J Ocul Pharmacol Ther，2010，26（5）：431-439.
［35］ DE PAIVA CS，SCHWARTZ CE，GJ?RSTRUP P，PFLUGFE-LDER SC.Resolvin E1（RX-10001） reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye［J］.Cornea，2012，31（11）：1299-1303.
［36］ CORTINA MS，BAZAN HE.Docosahexaenoic acid，protectins and dry eye［J］.Curr Opin Clini Nutr Metab Care，2011，14（2）：132-137.
［37］ KEATING SM，CLARK KR，STEFANICH CD，ARELLANO F，EDWARDS CP，BODARY SC，et al.Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the αL subunit of lymphocyte function-associated antigen-1［J］.Protein Sci，2006，15（2）：290-303.
［38］ ZHONG M，GADEK TR，BUI M，SHEN W，BURNIER J，BARR KJ，et al.Discovery and development of the potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye［J］.ACS Med Chem Lett，2012，3（3）：203-206.
［39］ DUSTIN ML，GROVES JT.Receptor signaling cluster in the immune synapse［J］.Annu Rev Biophys，2012，41：543-556.
［40］ MURPHY CJ，BENTLEY E，MILLER PE，MCINTYRE K，LEAT-HERBERRY G，DUBIELZIQ R，et al.The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist （SAR 1118） for the treatment of keratoconjunctivitis sicca in dogs［J］.Invest Ophthalmol Vis Sci，2011，52（6）：3174-3180.
［41］ DONNENFELD ED，KARPECKI PM，MAJMUDAR PA，NICHOLS KK，RAYCHAUDHURI A，ROY M，et al.Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease：a 1-year，multicenter，randomized，placebo-controlled study［J］.Cornea，2016，35（6）：741-748.
［42］ TEEPKER M，ANTHES N，KRIEG JC，VEDDER H.2-OH-estradiol，an endogenous hormone with neuroprotective function［J］.J Psychiatr Res，2003，37：517-523.
［43］ MENSE SM，CHHABRA J，BHAT HK.Preferential induction of cytochrome P450 1A1 over cytochrome P450 1B1 in human breast epithelial cells following exposure to quercetin［J］.J Steroid Biochem Mol Biol，2008，110：157-162.
［44］ RATHEE P，CHAUDHARY H，RATHEE S，RATHEE D，KUMAR V，KOHLI K.Mechanism of action of flavonoids as anti-inflammatory agents：a review［J］.Inflamm Allergy Drug Targets，2009，8：229-235.
［45］ CAVET ME，HARRINGTON KL，VOLLMER TR，WARD KW，ZHANG JZ.Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells［J］.Mol Vis，2011，17：533-542.
［46］ AKIHIRO H，ERINA O，TETSUYA K，TSUBOTA K.Evaluation of treatment of dry eye with 2-hydroxyestradiol using a dry eye rat model［J］.Mol Vis，2016，22：446-453.
［47］ UCHINO Y，KAWAKITA T，ISHII T，ISHII N，TSUBOTA K.A new mouse model of dry eye disease：oxidative stress affects functional decline in the lacrimal gland［J］.Cornea，2012，31（1）：63-67.
［48］ TSUBOTA K，KAWASHIMA M，INABA T，DOGRU M，MATSUMOTO Y，ISHIDA R，et al.The antiaging approach for the treatment of dry eye［J］.Cornea，2012，31（1）：3-8.
［49］ ANDRADE AS，SALOMON TB，BEHLING CS，MAHL CD，HACKENHAAR FS，PUTTI J，et al.Alpha-lipoic acid restores tear production in an animal model of dry eye［J］.Exp Eye Res，2014，3（120）：1-9.
［50］ LI Z，CHOI JH，OH HJ，PARK SH，LEE JB，YOON KC.Effect of eye drops containing a mixture of omega-3 essential fatty acids and hyaluronic acid on the ocular surface in desiccating stress-induced murine dry eye［J］.Curr Eye Res，2014，39（9）：871-878.
［51］ HUA X，DENG R，LI J，CHI W，SU Z，LIN J，et al.Protective effects of L-carnitine against oxidative injury by hyperosmolarity in human corneal epithelial cells［J］.Invest Ophthalmol and Vis Sci，2015，56（9）：5503-5511.
［52］ MACSAI MS.The role of omega-3 dietary supplementation in blepharitis and，eibomian gland dysfunction （an AOS thesis）［J］.Trans Am Ophthalmol Soc，2008，106：336-356.
［53］ KANGARI H，EFTEKHARI MH，SARDARI S，HASHEMI H，SALAMZADEH J，GHASSEMI-BROUMAND M，et al.Short-term consumption of oral omega-3 and dry eye syndrome［J］.Ophthalmology，2013，120（11）：2191-2196.
［54］ CHOI W，LEE JB，CUI L，LI Y，LI Z，CHOI JS，et al.Therapeutic efficacy of topically applied antioxidant medicinal plant extracts in a mouse model of experimental dry eye［J］.Oxid Med Cell Longev，2016，2016：4727415.
［55］ TAUBER J，DAVITT WF，BOCOSKY JE，NICHOLS KK，YERXA BR，SCHABERG AE，et al.Double-masked，placebo-controlled safety and efficacy trial of diquafosol tetrasodium （INS365） ophthalmic solution for the treatment od dry eye［J］.Cornea，2004，23（8）：784-792.
［56］ ONO M，TAKAMURA E，SHINOZAKI K，TSUMURA T，HAMANO T，YAQI Y，et al.Therapeutic effect of cevimeline on dry eye in patients with Sjgren’s syndrome：a randomized，double-blind clinical study［J］.Am J Ophthalmol，2004，138（1）：6-17.
［57］ TSIFETAKI N，KITSOS G，PASCHIDES CA，ALAMANOS Y，EFTAXIAS V，VOULGARI PV，et al.Oral pilocarpine for the treatment of ocular symptomes in patients with Sjgren’s syndrome：a randomised 12 week controlled study［J］.Ann Rheum Dis，2003，62（12）：1204-1207.
［58］ ESMAELI B，HARVEY JT，HEWLETT B.Immunohistochemical evidence for estrogen receptors in meibomian glands［J］.Ophthalmology，2000，107（1）：180-184.
［59］ GUASCHINO S，GRIMALDI E，SARTORE A，MUQITTU R，MANGINO F，BORTOLI P，et al.Visual function in menopause：the role of hormone replacement therapy［J］.Menopause，2003，10（1）：53-57.
［60］ PELIT A，BAGIS T，KAYASELC F，DURSUN D，AKOVA Y，AYDIN P.Tear function tests and conjunctival impression cytology before and after hormone replacement therapy in postmenopausal women［J］.Eur J Ophthalmol，2003，13（4）：337-342.
［61］ FENG YH，FENG G，PENG S，LI H.The effect of hormone replacement therapy on dry eye syndrome evaluated with Schimer Tst and break-up time［J］.J Ophthalmol，2015，2015：420302.
［62］ JACKSON WB.Management of dysfunctional tear syndrome：a Canadian consensus［J］.Can J Ophthalmol，2009，44（4）：385-394.
［63］ BAXTER S，LAIBSON P.Punctal plugs in the management of dry eyes［J］.Ocul Surf，2004，2（4）：255-265.
［64］ KAIDO M，ISHIDA R，DOGRU M，TSUBOTA K.Comparison of retention rates and complications of 2 different types of silicon lacrimal punctal plugs in the treatment of dry eye disease［J］.Am J Ophthalmol，2013，155（4）：649.
［65］ Ashley RB，Zale DM，Kelly DS，Mark DB，Stephanie AB.Punctal plug retention rates for the treatment of moderate to severe dry eye：a randomized，double-masked，controlled clinical trial［J］.Am J Ophthalmol，2015，160（2）：283-242.
［66］ AKSUNGUR P，DEMIRBILEK M，DENKBAS EB，VANDERV-OORT J，LUDWIG A，UNLU N.Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery：cellular toxicity，uptake，and kinetic studies［J］.J Control Release，2011，151：286-294.
［67］ SINGH K，NAIR AB，KUMAR A，KUMRIA R.Novel approaches in formulation and drug delivery using contact lenses［J］.J Basic Clin，2011，2（2）：87-101.
［68］ DJALILAN AR，NAGINENI CN，MAHESH SP，SMITH JA，NUSS-ENBLATT RB，HOOKS JJ.Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone，but not cyclosporin［J］.Cornea，2005，25（6）：709-714.
［69］ PATANE MA，COHEN A，FROM A，TORKILDSEN G，WELCH D，OUSLER III GW.Ocular iontophoresis of EGP-437 （dexamethasone phosphate） in dry eye patients：results of a randomized clinical trial［J］.Clin Ophthalmol，2011，5：633-643.
［70］ BILKHU PS，NAROO SA，WOLFSOHN JS.Effect of a commercially available warm compress on eyelid temperature and tear film in healthy eyes［J］.Optom Vis Sci，2014，91（2）：163-170.
［71］ BILKHU PS，NAROO SA，WOLFFSOHN JS.Randomised masked clinical trial of the MGDRx eyebag for the treatment of meibomian gland dysfunction-related evaporative dry eye［J］.Br J Ophthalmol，2014，98（12）：1707-1711.
相似文献/References:
[1]周朋义 彭广华.视网膜色素变性治疗的研究进展[J].眼科新进展,2012,32(5):000.
[2]杨红 阴正勤.眼球震颤的诊断与治疗研究进展[J].眼科新进展,2012,32(5):000.
[3]姜洋 李莹 王忠海 罗岩 金玉梅.小牛血去蛋白提取物眼用凝胶对LASIK 术后角膜修复及干眼的疗效观察[J].眼科新进展,2012,32(7):000.
[4]叶芬 王春红 陈银 施宇华 黄振平.人工泪液对糖尿病干眼患者泪河的影响[J].眼科新进展,2012,32(12):000.
[5]张磊 何彦津.无眼征Graves病患者的眼表损害[J].眼科新进展,2012,32(12):000.
[6]邵毅 周琼 易昀敏 余瑶 裴重刚 吴晓蓉 梅峰 占敏艳.鬼针草叶治疗非增生型糖尿病视网膜病变的临床研究[J].眼科新进展,2013,33(6):000.
[7]杨世琳 杜改萍 郝玉华.频域OCT观察Vogt-小柳-原田病患者病程中黄斑中心凹的图像特点[J].眼科新进展,2013,33(6):000.
[8]皮百木 穆红梅 张婉婷 郑娜 李娟.老年干眼患者眼表改变及其与睑板腺功能障碍的相关性[J].眼科新进展,2013,33(6):000.
[9]曾春梅 文勇 成旋.特发性息肉样脉络膜血管病变的治疗进展[J].眼科新进展,2013,33(7):000.
[10]张宏 马俊旗 安晓 叶向彧.围绝经期干眼患者眼表CXCR3表达与性激素的相关性分析[J].眼科新进展,2013,33(9):000.
[11]汪斌,黄歆,邵毅,等.鬼针草滴眼液预防去势雄兔干眼症的实验研究[J].眼科新进展,2014,34(12):1110.[doi:10.13389/j.cnki.rao.2014.0308]
WANG Bin,HUANG Xin,SHAO Yi,et al.Spanishneedles herb eye drops for dry eye in castrated rabbit model[J].Recent Advances in Ophthalmology,2014,34(2):1110.[doi:10.13389/j.cnki.rao.2014.0308]
[12]邵毅,石文卿.2018美国眼科学会干眼指南解读[J].眼科新进展,2019,39(12):1101.[doi:10.13389/j.cnki.rao.2019.0253]
SHAO Yi,SHI Wen-Qing.Interpretation of 2018 Dry Eye Syndrome Preferred Practice Pattern (DEsPPP)[J].Recent Advances in Ophthalmology,2019,39(2):1101.[doi:10.13389/j.cnki.rao.2019.0253]
[13]邵毅,吴康瑞,叶蕾.干眼的发病机制及治疗研究进展[J].眼科新进展,2020,40(4):301.[doi:10.13389/j.cnki.rao.2020.0070]
SHAO Yi,WU Kangrui,YE Lei.Recent advance in dry eye pathogenesis and treatment[J].Recent Advances in Ophthalmology,2020,40(2):301.[doi:10.13389/j.cnki.rao.2020.0070]